{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:10:48Z","timestamp":1786374648047,"version":"build-2736575974"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SEAP- Semilla \u201cAntonio Llombart Bosch\u201d for Translational Research in Pathology","award":["2021-0297"],"award-info":[{"award-number":["2021-0297"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02319-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:46:10Z","timestamp":1780577170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-0924","authenticated-orcid":false,"given":"Yoel G.","family":"Montoyo-Pujol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4370-5468","authenticated-orcid":false,"given":"Pascual","family":"Mart\u00ednez-Peinado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-1185","authenticated-orcid":false,"given":"Sandra","family":"Pascual-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0731-6975","authenticated-orcid":false,"given":"Samanta","family":"Ortu\u00f1o-Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-901X","authenticated-orcid":false,"given":"Jos\u00e9 J.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Lozano-Cubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-118X","authenticated-orcid":false,"given":"Elena","family":"Castell\u00f3n-Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-1343","authenticated-orcid":false,"given":"Silvia","family":"Delgado-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-127X","authenticated-orcid":false,"given":"Tina A.","family":"Mart\u00edn-Bay\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-2725","authenticated-orcid":false,"given":"Hortensia","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-3427","authenticated-orcid":false,"given":"Angela","family":"Ramos-Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-0604","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Sempere-Ortells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2899-2908","authenticated-orcid":false,"given":"Gloria","family":"Peir\u00f3-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"2319_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6797","key":"2319_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"5","key":"2319_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"4","key":"2319_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1746","volume":"9","author":"DG DeNardo","year":"2007","unstructured":"DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.","journal-title":"Breast Cancer Res"},{"key":"2319_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010020","author":"D Nagarajan","year":"2018","unstructured":"Nagarajan D, McArdle SEB. Immune landscape of breast cancers. Biomedicines. 2018. https:\/\/doi.org\/10.3390\/biomedicines6010020.","journal-title":"Biomedicines"},{"key":"2319_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156409","volume":"172","author":"M Bessaad","year":"2023","unstructured":"Bessaad M, et al. Assessing serum cytokine profiles in inflammatory breast cancer patients using Luminex(R) technology. Cytokine. 2023;172:156409.","journal-title":"Cytokine"},{"issue":"10","key":"2319_CR7","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1172\/JCI57099","volume":"121","author":"H Korkaya","year":"2011","unstructured":"Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011;121(10):3804\u20139.","journal-title":"J Clin Invest"},{"key":"2319_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156590","volume":"179","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, et al. Expression and function of cytokine interleukin-22 gene in the tumor microenvironment of triple negative breast cancer. Cytokine. 2024;179:156590.","journal-title":"Cytokine"},{"issue":"2","key":"2319_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx W, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6(2):e1253654.","journal-title":"Oncoimmunology"},{"key":"2319_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21624X","volume":"8","author":"S Jabeen","year":"2019","unstructured":"Jabeen S, Espinoza J, Torland L. Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. Oncoimmunology. 2019;8:1\u201311. https:\/\/doi.org\/10.1080\/21624X.","journal-title":"Oncoimmunology"},{"issue":"2","key":"2319_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","volume":"45","author":"JM Zhang","year":"2007","unstructured":"Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27\u201337.","journal-title":"Int Anesthesiol Clin"},{"issue":"2","key":"2319_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/jcp.24441","volume":"229","author":"J Richmond","year":"2014","unstructured":"Richmond J, et al. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J Cell Physiol. 2014;229(2):139\u201347.","journal-title":"J Cell Physiol"},{"key":"2319_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2019.104798","volume":"28","author":"K Chen","year":"2020","unstructured":"Chen K, et al. Cytokine secretion in breast cancer cells\u2013MILLIPLEX assay data. Data Brief. 2020;28:104798.","journal-title":"Data Brief"},{"key":"2319_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020342","author":"MJ Stone","year":"2017","unstructured":"Stone MJ, et al. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18020342.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2319_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2319_CR16","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1038\/s41598-019-40514-9","volume":"9","author":"JK Thomas","year":"2019","unstructured":"Thomas JK, et al. CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival. Sci Rep. 2019;9(1):4014.","journal-title":"Sci Rep"},{"issue":"Pt 3","key":"2319_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.semcancer.2021.12.011","volume":"86","author":"S Raza","year":"2022","unstructured":"Raza S, et al. Multifaceted role of chemokines in solid tumors: from biology to therapy. Semin Cancer Biol. 2022;86(Pt 3):1105\u201321.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2319_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrc2507","volume":"8","author":"B Seruga","year":"2008","unstructured":"Seruga B, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2319_CR19","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","volume":"14","author":"BE Lippitz","year":"2013","unstructured":"Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218\u201328.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2319_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41416-023-02527-0","volume":"130","author":"DP Saldajeno","year":"2024","unstructured":"Saldajeno DP, et al. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients. Br J Cancer. 2024;130(6):1023\u201335.","journal-title":"Br J Cancer"},{"issue":"34","key":"2319_CR21","doi-asserted-by":"publisher","first-page":"14252","DOI":"10.1073\/pnas.1103125108","volume":"108","author":"A Carlsson","year":"2011","unstructured":"Carlsson A, et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A. 2011;108(34):14252\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2319_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-39476-9","volume":"9","author":"K Kawaguchi","year":"2019","unstructured":"Kawaguchi K, et al. Alteration of specific cytokine expression patterns in patients with breast cancer. Sci Rep. 2019;9(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"5","key":"2319_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1158\/0008-5472.CAN-16-1373","volume":"77","author":"L Wang","year":"2017","unstructured":"Wang L, et al. IL6 signaling in peripheral blood T cells predicts clinical outcome in breast cancer. Cancer Res. 2017;77(5):1119\u201326.","journal-title":"Cancer Res"},{"issue":"1","key":"2319_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12964-021-00746-7","volume":"19","author":"E Persson","year":"2021","unstructured":"Persson E, et al. Patient-derived scaffolds influence secretion profiles in cancer cells mirroring clinical features and breast cancer subtypes. Cell Commun Signal. 2021;19(1):66.","journal-title":"Cell Commun Signal"},{"key":"2319_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000876","author":"O Garrone","year":"2020","unstructured":"Garrone O, et al. Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. ESMO Open. 2020. https:\/\/doi.org\/10.1136\/esmoopen-2020-000876.","journal-title":"ESMO Open"},{"key":"2319_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01413","volume":"11","author":"J Valdes-Ferrada","year":"2020","unstructured":"Valdes-Ferrada J, et al. Peripheral blood classical monocytes and plasma interleukin 10 are associated to neoadjuvant chemotherapy response in breast cancer patients. Front Immunol. 2020;11:1413.","journal-title":"Front Immunol"},{"issue":"5","key":"2319_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s10753-023-01830-5","volume":"46","author":"R Kern","year":"2023","unstructured":"Kern R, et al. The expression of CTLA-4 in breast tumors and tumor-infiltrating leukocytes affects patients\u2019 systemic inflammatory status and varies according to their molecular subtypes. Inflammation. 2023;46(5):1639\u201352.","journal-title":"Inflammation"},{"issue":"9","key":"2319_CR28","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.21873\/anticanres.13691","volume":"39","author":"N Inoue","year":"2019","unstructured":"Inoue N, et al. High serum levels of interleukin-18 are associated with worse outcomes in patients with breast cancer. Anticancer Res. 2019;39(9):5009\u201318.","journal-title":"Anticancer Res"},{"issue":"10","key":"2319_CR29","doi-asserted-by":"publisher","first-page":"8611","DOI":"10.18632\/aging.205828","volume":"16","author":"X Zhao","year":"2024","unstructured":"Zhao X, et al. A novel signature incorporating genes related to lipid metabolism and immune for prognostic and functional prediction of breast cancer. Aging (Albany NY). 2024;16(10):8611\u201329.","journal-title":"Aging (Albany NY)"},{"key":"2319_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05793-y","author":"T Vilsmaier","year":"2020","unstructured":"Vilsmaier T, et al. Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status. Arch Gynecol Obstet. 2020. https:\/\/doi.org\/10.1007\/s00404-020-05793-y.","journal-title":"Arch Gynecol Obstet"},{"issue":"33","key":"2319_CR31","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1111\/1759-7714.15119","volume":"14","author":"Z Peng","year":"2023","unstructured":"Peng Z, et al. Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients. Thorac Cancer. 2023;14(33):3282\u201394.","journal-title":"Thorac Cancer"},{"key":"2319_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084561","author":"JI Yi","year":"2024","unstructured":"Yi JI, et al. Interferon-Gamma secretion is significantly decreased in stage III breast cancer patients. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25084561.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2319_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/jir.2023.0157","volume":"44","author":"E Kontomanolis","year":"2024","unstructured":"Kontomanolis E, et al. Cytokine plasma levels in breast cancer patients, before and after surgery. J Interferon Cytokine Res. 2024;44(3):135\u201342.","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"2319_CR34","first-page":"206","volume":"5","author":"C Streckfus","year":"2018","unstructured":"Streckfus C, et al. Profile of tumor-associated cytokines among breast cancer patients: a preliminary study. J Cancer Sci Clin Oncol. 2018;5(2):206.","journal-title":"J Cancer Sci Clin Oncol"},{"issue":"2","key":"2319_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-013-2549-3","volume":"139","author":"CC Hong","year":"2013","unstructured":"Hong CC, et al. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat. 2013;139(2):477\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"2319_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102631","volume":"52","author":"L Wang","year":"2020","unstructured":"Wang L, et al. Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes. EBioMedicine. 2020;52:102631.","journal-title":"EBioMedicine"},{"issue":"5","key":"2319_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403\u201310.","journal-title":"Histopathology"},{"issue":"2","key":"2319_CR38","first-page":"865","volume":"35","author":"E Richardsen","year":"2015","unstructured":"Richardsen E, et al. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res. 2015;35(2):865\u201374.","journal-title":"Anticancer Res"},{"issue":"5","key":"2319_CR39","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3892\/ijo.2016.3680","volume":"49","author":"J Ding","year":"2016","unstructured":"Ding J, et al. CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol. 2016;49(5):2064\u201374.","journal-title":"Int J Oncol"},{"issue":"3","key":"2319_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115177","volume":"5","author":"M Hollm\u00e9n","year":"2016","unstructured":"Hollm\u00e9n M, et al. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology. 2016;5(3):e1115177.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2319_CR41","first-page":"7","volume":"2","author":"KO Osuala","year":"2014","unstructured":"Osuala KO, Sloane BF. Many roles of CCL20: emphasis on breast cancer. Postdoc J. 2014;2(3):7.","journal-title":"Postdoc J"},{"issue":"2","key":"2319_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/cancers2020970","volume":"2","author":"KD Lynn","year":"2010","unstructured":"Lynn KD, Roland CL, Brekken RA. VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers. 2010;2(2):970\u201388.","journal-title":"Cancers"},{"issue":"19","key":"2319_CR43","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1158\/0008-5472.CAN-13-0842","volume":"73","author":"A Sio","year":"2013","unstructured":"Sio A, et al. Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. Cancer Res. 2013;73(19):5892\u2013904.","journal-title":"Cancer Res"},{"issue":"6","key":"2319_CR44","doi-asserted-by":"publisher","first-page":"E566","DOI":"10.1073\/pnas.1424927112","volume":"112","author":"A-J Casbon","year":"2015","unstructured":"Casbon A-J, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci. 2015;112(6):E566\u201375.","journal-title":"Proc Natl Acad Sci"},{"issue":"21","key":"2319_CR45","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.3390\/cancers14215460","volume":"14","author":"HT Amer","year":"2022","unstructured":"Amer HT, Stein U, El Tayebi HM. The monocyte, a maestro in the tumor microenvironment (TME) of breast cancer. Cancers. 2022;14(21):5460.","journal-title":"Cancers"},{"issue":"1","key":"2319_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/1878-0261.12598","volume":"14","author":"GK Katara","year":"2020","unstructured":"Katara GK, et al. Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer. Mol Oncol. 2020;14(1):211\u201324.","journal-title":"Mol Oncol"},{"issue":"5","key":"2319_CR47","first-page":"2398","volume":"4","author":"P Karimzadeh","year":"2023","unstructured":"Karimzadeh P, et al. Correlation of serum hematopoietic growth factors with breast cancer. J Clin Images Med Case Rep. 2023;4(5):2398.","journal-title":"J Clin Images Med Case Rep"},{"issue":"1","key":"2319_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13046-024-03074-z","volume":"43","author":"SC Pitts","year":"2024","unstructured":"Pitts SC, Schlom J, Donahue RN. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. J Exp Clin Cancer Res. 2024;43(1):155.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2319_CR49","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.3390\/ijms24044002","volume":"24","author":"O Habanjar","year":"2023","unstructured":"Habanjar O, et al. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci. 2023;24(4):4002.","journal-title":"Int J Mol Sci"},{"key":"2319_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1684\/ecn.2020.0447","volume":"31","author":"P Karimzadeh","year":"2020","unstructured":"Karimzadeh P, et al. Quantification of angiogenic factors and their clinicopathological associations in breast cancer. Eur Cytokine Netw. 2020;31:68\u201375.","journal-title":"Eur Cytokine Netw"},{"key":"2319_CR51","doi-asserted-by":"crossref","unstructured":"Talaat IM, Elemam NM, Abdullah HW. CD68, CD86 and CD163 expression profile in breast cancer molecular subtypes. FASEB J , 2022;36.","DOI":"10.1096\/fasebj.2022.36.S1.R3106"},{"issue":"2","key":"2319_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.21037\/atm-22-6245","volume":"11","author":"C Kang","year":"2023","unstructured":"Kang C, et al. Landscape of costimulatory molecule signature in breast cancer and its prognostic significance. Ann Transl Med. 2023;11(2):59.","journal-title":"Ann Transl Med"},{"issue":"8","key":"2319_CR53","first-page":"3282","volume":"6","author":"T Ueno","year":"2000","unstructured":"Ueno T, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6(8):3282\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"2319_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000077718","volume":"25","author":"A Lebrecht","year":"2004","unstructured":"Lebrecht A, et al. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004;25(1\u20132):14\u20137.","journal-title":"Tumour Biol"},{"issue":"21","key":"2319_CR55","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.1158\/1078-0432.CCR-04-0812","volume":"10","author":"IH Benoy","year":"2004","unstructured":"Benoy IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157\u201362.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2319_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-023-01631-6","volume":"25","author":"FB Gunnarsdottir","year":"2023","unstructured":"Gunnarsdottir FB, et al. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study. Breast Cancer Res. 2023;25(1):29.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2319_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3892\/br.2016.709","volume":"5","author":"B Celik","year":"2016","unstructured":"Celik B, et al. CXCL8, IL-1\u03b2 and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients. Biomed Rep. 2016;5(2):259\u201363.","journal-title":"Biomed Rep"},{"issue":"4","key":"2319_CR58","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov I, et al. Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti\u2013PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2319_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-013-0634-4","volume":"30","author":"L Ren","year":"2013","unstructured":"Ren L, et al. Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130\/STAT3 pathway. Med Oncol. 2013;30:1\u20139.","journal-title":"Med Oncol"},{"issue":"4","key":"2319_CR60","first-page":"350","volume":"39","author":"A Khodadadi","year":"2014","unstructured":"Khodadadi A, et al. IL-23\/IL-27 ratio in peripheral blood of patients with breast cancer. Iran J Med Sci. 2014;39(4):350.","journal-title":"Iran J Med Sci"},{"key":"2319_CR61","doi-asserted-by":"crossref","unstructured":"Liu C et al. A panel containing PD-1, IL-2R\u03b1, IL-10, and CA15\u20133 as a biomarker to discriminate breast cancer from benign breast disease. Cancer Manag Res 2018;1749\u20131761.","DOI":"10.2147\/CMAR.S160452"},{"issue":"5","key":"2319_CR62","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clbc.2019.03.008","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, et al. Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Breast Cancer. 2019;19(5):326-332. e1.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"2319_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020500","volume":"13","author":"NE Kushlinskii","year":"2025","unstructured":"Kushlinskii NE, et al. Assessing the clinical relevance of soluble PD-1 and PD-L1: a multi-cohort study across diverse tumor types and prognostic implications. Biomedicines. 2025;13(2):500.","journal-title":"Biomedicines"},{"issue":"3","key":"2319_CR64","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1084\/jem.20102131","volume":"208","author":"A Pedroza-Gonzalez","year":"2011","unstructured":"Pedroza-Gonzalez A, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011;208(3):479\u201390.","journal-title":"J Exp Med"},{"issue":"7","key":"2319_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1196299","volume":"5","author":"KS Baghel","year":"2016","unstructured":"Baghel KS, et al. Macrophages promote matrix protrusive and invasive function of breast cancer cells via MIP-1\u03b2 dependent upregulation of MYO3A gene in breast cancer cells. Oncoimmunology. 2016;5(7):e1196299.","journal-title":"Oncoimmunology"},{"issue":"8","key":"2319_CR66","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1158\/1078-0432.CCR-04-0861","volume":"11","author":"A Irie","year":"2005","unstructured":"Irie A, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 2005;11(8):2962\u20138.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2319_CR67","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/biomedicines9101383","volume":"9","author":"M-H Ju","year":"2021","unstructured":"Ju M-H, et al. Association of galectin 9 expression with immune cell infiltration, programmed cell death ligand-1 expression, and patient\u2019s clinical outcome in triple-negative breast cancer. Biomedicines. 2021;9(10):1383.","journal-title":"Biomedicines"},{"issue":"15","key":"2319_CR68","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.3390\/cancers15153809","volume":"15","author":"A Funkhouser","year":"2023","unstructured":"Funkhouser A, et al. Pattern analysis of serum galectins-1,-3, and-9 in breast cancer. Cancers. 2023;15(15):3809.","journal-title":"Cancers"},{"issue":"8","key":"2319_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1178438","volume":"5","author":"C Ghirelli","year":"2016","unstructured":"Ghirelli C, et al. No evidence for TSLP pathway activity in human breast cancer. Oncoimmunology. 2016;5(8):e1178438.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2319_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2025.14928","volume":"29","author":"S Marcella","year":"2025","unstructured":"Marcella S, et al. Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: a preliminary study. Oncol Lett. 2025;29(4):1\u20139.","journal-title":"Oncol Lett"},{"issue":"6","key":"2319_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.acthis.2011.10.007","volume":"114","author":"DAP de Campos Zuccari","year":"2012","unstructured":"de Campos Zuccari DAP, et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem. 2012;114(6):571\u20136.","journal-title":"Acta Histochem"},{"key":"2319_CR72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10522-010-9280-9","volume":"11","author":"M Provinciali","year":"2010","unstructured":"Provinciali M, et al. Inflammation, aging, and cancer vaccines. Biogerontology. 2010;11:615\u201326.","journal-title":"Biogerontology"},{"key":"2319_CR73","doi-asserted-by":"crossref","unstructured":"Ullah A et al. Age-related and postmenopausal breast cancer progression and treatment management: The significance of pro-inflammatory cytokines and CXC chemokines. Genes Dis 2025;101606.","DOI":"10.1016\/j.gendis.2025.101606"},{"issue":"10","key":"2319_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1184","volume":"9","author":"L Berben","year":"2020","unstructured":"Berben L, et al. Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. Clin Transl Immunol. 2020;9(10):e1184.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"2319_CR75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1166\/jbn.2024.3738","volume":"20","author":"M Liu","year":"2024","unstructured":"Liu M, et al. C-C Motif Chemokine Ligand 4 Positive (CCL4+) neutrophils negatively influence the tumor immune microenvironment by regulating macrophages. J Biomed Nanotechnol. 2024;20(1):103\u201310.","journal-title":"J Biomed Nanotechnol"},{"issue":"9","key":"2319_CR76","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/2159-8290.CD-18-1454","volume":"9","author":"J Sceneay","year":"2019","unstructured":"Sceneay J, et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discov. 2019;9(9):1208\u201327.","journal-title":"Cancer Discov"},{"issue":"15","key":"2319_CR77","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1158\/1078-0432.CCR-21-1549","volume":"27","author":"AML Wu","year":"2021","unstructured":"Wu AML, et al. Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis. Clin Cancer Res. 2021;27(15):4422\u201334.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2319_CR78","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/0008-5472.CAN-19-2288","volume":"80","author":"J-H Jang","year":"2020","unstructured":"Jang J-H, et al. Breast cancer cell\u2013derived soluble CD44 promotes tumor progression by triggering macrophage IL1\u03b2 production. Cancer Res. 2020;80(6):1342\u201356.","journal-title":"Cancer Res"},{"issue":"6","key":"2319_CR79","first-page":"3123","volume":"36","author":"A Koenig","year":"2016","unstructured":"Koenig A, et al. Determination of interleukin-4,-5,-6,-8 and-13 in serum of patients with breast cancer before treatment and its correlation to circulating tumor cells. Anticancer Res. 2016;36(6):3123\u201330.","journal-title":"Anticancer Res"},{"key":"2319_CR80","doi-asserted-by":"publisher","first-page":"1019247","DOI":"10.3389\/fonc.2022.1019247","volume":"12","author":"G Liu","year":"2022","unstructured":"Liu G, et al. Expression analysis of cytokines IL-5, IL-6, IL-8, IL-17 and VEGF in breast cancer patients. Front Oncol. 2022;12:1019247.","journal-title":"Front Oncol"},{"issue":"1","key":"2319_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, et al. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22(1):121.","journal-title":"Mol Cancer"},{"key":"2319_CR82","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.intimp.2017.08.031","volume":"52","author":"F-P You","year":"2017","unstructured":"You F-P, et al. Th9 cells promote antitumor immunity via IL-9 and IL-21 and demonstrate atypical cytokine expression in breast cancer. Int Immunopharmacol. 2017;52:163\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2319_CR83","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.4049\/jimmunol.2000383","volume":"206","author":"S Das","year":"2021","unstructured":"Das S, et al. IL-9 abrogates the metastatic potential of breast cancer by controlling extracellular matrix remodeling and cellular contractility. J Immunol. 2021;206(11):2740\u201352.","journal-title":"J Immunol"},{"issue":"3","key":"2319_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057469","volume":"8","author":"KD Natividad","year":"2013","unstructured":"Natividad KD, et al. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS ONE. 2013;8(3):e57469.","journal-title":"PLoS ONE"},{"issue":"1","key":"2319_CR85","first-page":"30","volume":"7","author":"E Sheikhpour","year":"2018","unstructured":"Sheikhpour E, et al. A survey on the role of interleukin-10 in breast cancer: a narrative. Rep Biochem Mol Biol. 2018;7(1):30.","journal-title":"Rep Biochem Mol Biol"},{"key":"2319_CR86","first-page":"1","volume-title":"Handbook of cancer and immunology","author":"KE Huntington","year":"2023","unstructured":"Huntington KE, El-Deiry WS. The role of soluble immune checkpoints in cancer immunotherapy. In: Handbook of cancer and immunology. Springer; 2023. p. 1\u201344."},{"key":"2319_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155836","volume":"152","author":"N Todorovi\u0107-Rakovi\u0107","year":"2022","unstructured":"Todorovi\u0107-Rakovi\u0107 N, et al. The prognostic significance of serum interferon-gamma (IFN-\u03b3) in hormonally dependent breast cancer. Cytokine. 2022;152:155836.","journal-title":"Cytokine"},{"issue":"8","key":"2319_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084561","volume":"25","author":"JI Yi","year":"2024","unstructured":"Yi JI, et al. Interferon-gamma secretion is significantly decreased in stage III breast cancer patients. Int J Mol Sci. 2024;25(8):4561.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2319_CR89","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1038\/s41598-024-56681-3","volume":"14","author":"Z-L Jing","year":"2024","unstructured":"Jing Z-L, et al. Interferon-\u03b3 in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells. Sci Rep. 2024;14(1):6053.","journal-title":"Sci Rep"},{"issue":"6","key":"2319_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1530\/ERC-13-0198","volume":"20","author":"S Aharinejad","year":"2013","unstructured":"Aharinejad S, et al. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer. 2013;20(6):777\u201383.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2319_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005869","volume":"16","author":"W Chen","year":"2018","unstructured":"Chen W, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16(7):e2005869.","journal-title":"PLoS Biol"},{"issue":"6","key":"2319_CR92","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/JCMA.0000000000001233","volume":"88","author":"X Zhao","year":"2025","unstructured":"Zhao X, et al. Elevated CCL20 expression was associated with poor prognosis for breast cancer. J Chin Med Assoc. 2025;88(6):469\u201380.","journal-title":"J Chin Med Assoc"},{"issue":"4","key":"2319_CR93","first-page":"316","volume":"21","author":"A Demir","year":"2024","unstructured":"Demir A, et al. Blood cytokine profile in breast cancer: focusing on differences among molecular subtypes. Iran J Immunol. 2024;21(4):316\u201327.","journal-title":"Iran J Immunol"},{"issue":"8","key":"2319_CR94","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231171762","volume":"51","author":"H Zhai","year":"2023","unstructured":"Zhai H, et al. CCL20 is a potential therapeutic target associated with immune infiltration in breast cancer. J Int Med Res. 2023;51(8):03000605231171762.","journal-title":"J Int Med Res"},{"issue":"3","key":"2319_CR95","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211039590","volume":"104","author":"K Gonda","year":"2021","unstructured":"Gonda K, et al. Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer. Sci Prog. 2021;104(3):00368504211039590.","journal-title":"Sci Prog"},{"issue":"3","key":"2319_CR96","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2310\/JIM.0000000000000046","volume":"62","author":"D Lu","year":"2014","unstructured":"Lu D, et al. Clinical implications of the interleukin 27 serum level in breast cancer. J Investig Med. 2014;62(3):627\u201331.","journal-title":"J Investig Med"},{"issue":"47","key":"2319_CR97","doi-asserted-by":"publisher","first-page":"39273","DOI":"10.1074\/jbc.M509446200","volume":"280","author":"RD Lester","year":"2005","unstructured":"Lester RD, et al. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK\/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 2005;280(47):39273\u20137.","journal-title":"J Biol Chem"},{"issue":"5","key":"2319_CR98","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41419-019-1594-1","volume":"10","author":"M Liang","year":"2019","unstructured":"Liang M, et al. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis. Cell Death Dis. 2019;10(5):353.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2319_CR99","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta C, et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 2019;25(9):2769\u201382.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2319_CR100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-019-05135-w","volume":"175","author":"L Guo","year":"2019","unstructured":"Guo L, et al. A high-risk luminal A dominant breast cancer subtype with increased mobility. Breast Cancer Res Treat. 2019;175(2):459\u201372.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2319_CR101","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-018-4664-7","volume":"169","author":"S Jansson","year":"2018","unstructured":"Jansson S, et al. The PDGF pathway in breast cancer is linked to tumour aggressiveness, Triple-Negative subtype and early recurrence. Breast Cancer Res Treat. 2018;169(2):231\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2319_CR102","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/bcr1648","volume":"9","author":"C Chavey","year":"2007","unstructured":"Chavey C, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9(1):R15.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"2319_CR103","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/CAD.0000000000001678","volume":"36","author":"S Tang","year":"2025","unstructured":"Tang S, et al. High CXCL8 expression predicting poor prognosis in Triple-Negative breast cancer. Anticancer Drugs. 2025;36(3):246\u201352.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2319_CR104","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s12276-023-01150-6","volume":"56","author":"E-J Park","year":"2024","unstructured":"Park E-J, Lee C-W. Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies. Exp Mol Med. 2024;56(1):100\u20139.","journal-title":"Exp Mol Med"},{"issue":"10","key":"2319_CR105","first-page":"2809","volume":"118","author":"Z-Z Yang","year":"2011","unstructured":"Yang Z-Z, et al. Soluble IL-2R\u03b1 facilitates IL-2\u2013mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood J Am Soc Hematol. 2011;118(10):2809\u201320.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"2319_CR106","first-page":"3309","volume":"25","author":"L He","year":"2005","unstructured":"He L, et al. Blockade of B7\u2013H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res. 2005;25(5):3309\u201313.","journal-title":"Anticancer Res"},{"issue":"3","key":"2319_CR107","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CJI.0b013e318210ed0e","volume":"34","author":"M-Y Song","year":"2011","unstructured":"Song M-Y, et al. Enhancement of vaccine-induced primary and memory CD8+ t-cell responses by soluble PD-1. J Immunother. 2011;34(3):297\u2013306.","journal-title":"J Immunother"},{"issue":"8","key":"2319_CR108","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.7314\/APJCP.2012.13.8.4031","volume":"13","author":"OA Elhag","year":"2012","unstructured":"Elhag OA, et al. Reconstructed Adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev. 2012;13(8):4031\u20136.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2319_CR109","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/mt.2012.252","volume":"21","author":"S-P Shin","year":"2013","unstructured":"Shin S-P, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688\u201395.","journal-title":"Mol Ther"},{"issue":"9","key":"2319_CR110","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/eji.200635978","volume":"36","author":"H Kuipers","year":"2006","unstructured":"Kuipers H, et al. Contribution of the PD-1 ligands\/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006;36(9):2472\u201382.","journal-title":"Eur J Immunol"},{"key":"2319_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587460","volume":"11","author":"M Khan","year":"2020","unstructured":"Khan M, et al. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460.","journal-title":"Front Immunol"},{"issue":"1","key":"2319_CR112","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12935-025-03729-7","volume":"25","author":"V Schweihofer","year":"2025","unstructured":"Schweihofer V, et al. Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy. Cancer Cell Int. 2025;25(1):120.","journal-title":"Cancer Cell Int"},{"issue":"28","key":"2319_CR113","doi-asserted-by":"publisher","first-page":"46020","DOI":"10.18632\/oncotarget.17546","volume":"8","author":"N Li","year":"2017","unstructured":"Li N, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget. 2017;8(28):46020.","journal-title":"Oncotarget"},{"issue":"4","key":"2319_CR114","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1561120","volume":"8","author":"B Bian","year":"2019","unstructured":"Bian B, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8(4):e1561120.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2319_CR115","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cancers13030398","volume":"13","author":"H Vajavaara","year":"2021","unstructured":"Vajavaara H, et al. Soluble PD-1 but not PD-L1 levels predict poor outcome in patients with high-risk diffuse large B-cell lymphoma. Cancers. 2021;13(3):398.","journal-title":"Cancers"},{"issue":"4","key":"2319_CR116","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/br.2025.1948","volume":"22","author":"SE P\u00e9rez-Picazo","year":"2025","unstructured":"P\u00e9rez-Picazo SE, et al. High serum levels of soluble PD\u20111 and PD\u2011L1 are associated with advanced clinical stages in patients with cervical cancer. Biomedical Reports. 2025;22(4):70.","journal-title":"Biomedical Reports"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02319-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:03:42Z","timestamp":1786370622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02319-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the ethical standards of the Institutional Ethics Committee of Dr. Balmis University General Hospital (protocol code PI2021-141, approval number 2021-0297, approved on October 29, 2021). Written informed consent was obtained from all participants prior to inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}